BACKGROUND: Micro-immuno¯uorescence (MIF) is widely used for chlamydia antibody testing (CAT). Recently a species-speci®c MIF and three enzyme-linked immunosorbent assay (ELISA) tests have been introduced. We compared ®ve commercially available CAT tests, using laparoscopy as a reference, and evaluated whether combinations of tests could improve the predictive value of CAT. METHODS: In a consecutive cohort of 315 subfertile women, results of the ®ve CAT tests were correlated to ®ndings at laparoscopy. Likelihood and odds ratios (OR) were calculated for single tests and for combinations of tests. RESULTS: Of the tests evaluated, MIF Labsystems had the best diagnostic performance (OR 15.7), while pELISA Medac (OR 8.2) was the best of the three ELISA tests. Stepwise logistic regression analysis showed that performance of MIF Labsystems could not be improved by adding a second test. Signi®cant cross-reactivity with C. pneumoniae antibodies was found in all tests evaluated, except in pELISA Medac. CONCLUSIONS: In screening for tubal factor subfertility, MIF Labsystems was superior to the ELISA tests evaluated, and combining two CAT tests did not improve its predictive value. Economic analysis will show whether serial testing by pELISA Medac, and retesting positive samples by MIF Labsystems, is most cost-effective. In CAT, cross-reactivity with C. pneumoniae antibodies is still a major concern.
Introduction
Since the association between Chlamydia trachomatis antibodies in serum and tubal pathology was noticed (Punnonen et al., 1979) , chlamydia antibody testing (CAT) has been used in the fertility work-up as a screening test for tubal factor subfertility. A widely used test for CAT is the microimmuno¯uorescence test (MIF), which has been considered the gold standard in the serological diagnosis of chlamydia infection (Dowell et al., 2001) . Initially, antigens from elementary bodies of each of the serotypes of C. trachomatis were included in the MIF test, which provided serotypespeci®c antibody testing (Wang and Grayston, 1970) . Later, for practical reasons, the number of antigens has been reduced by pooling antigens of epidemiologically related serotypes, or by using one broadly reacting serotype (usually L2) (Treharne et al., 1977) . However, in modi®ed MIF tests, cross-reactivity between C. trachomatis and C. pneumoniae occurs (Mannion et al., 1991; Gijsen et al., 2001) . To overcome this, speciesspeci®c MIF tests have been developed. In these tests, the cross-reactivity between the different chlamydia species has been reduced by subtracting lipopolysaccharide (LPS), a common component of the outer membrane of all Chlamydiaceae, from C. pneumoniae and C. trachomatis antigens. Other disadvantages of the MIF tests are that they are labour intensive, their reading is observer dependent, and interlaboratory variation is signi®cant . To overcome these drawbacks, enzyme-linked immunosorbent assay (ELISA) tests with high speci®city have been developed, using LPS-stripped elementary bodies as antigens (Ossewaarde et al., 1994) . Recently assays have become commercially available in which speci®c synthetic peptides are used. These peptides are based on the major outer membrane protein (MOMP) of C. trachomatis, which contains species-speci®c and serotype-speci®c epitopes (Na Èrva Ènen et al., 1997) . These ELISA tests are easy to perform and are well standardized (Tuuminen et al., 2000) . The value of CAT using ELISA and species-speci®c MIF in predicting tubal factor subfertility has not been evaluated yet.
The ®rst aim of this study was to compare ®ve commercially available chlamydia IgG antibody tests in their accuracy to predict tubal factor subfertility, using laparoscopy as a reference. The performances of a species-speci®c MIF test and three ELISA tests were compared with ®ndings obtained with a MIF test that had been used in our hospital for 10 years. Cross-reactivity with C. pneumoniae antibodies was evaluated in the ®ve CAT tests as a possible cause of false positive CAT results. The second aim was to evaluate whether combinations of two tests could improve the predictive value of CAT.
Materials and methods
The study was performed in female patients who sought treatment for subfertility in our clinic, a tertiary care centre. Since 1992, CAT using MIF has been a routine procedure in our fertility work-up. In all female patients, blood is drawn at their initial visit and a MIF test for C. trachomatis IgG antibodies (Biomerieux, The Netherlands) is performed, and all spare serum samples are cryopreserved at ±20°C. CAT is used for selecting patients at high risk for tubal factor subfertility. Patients who have antibody titres <64 are considered low risk and tubal factor is evaluated initially by hysterosalpingography (HSG). In cases of an abnormal HSG or failure of pregnancy to occur in the 6 months following HSG, the fertility work-up is concluded by laparoscopy and tubal testing with methylene blue dye. In patients who have antibody titres b64, no HSG is performed, but tubal factor is evaluated primarily by laparoscopy.
Between June 1992 and September 2001, 315 successive patients underwent laparoscopy as part of their fertility work-up. All took part in this study. Patients who had undergone previous pelvic surgery (except for an uneventful appendectomy or Caesarean section) were excluded.
All laparoscopy reports were scored by two gynaecologists, who were blinded for the CAT results. For the sake of the study, tubal pathology at laparoscopy was de®ned as extensive periadnexal adhesions and/or distal occlusion of both tubes, since this has been shown to re¯ect chlamydia associated tubal disease most accurately (Land et al., 1998) .
After thawing the cryopreserved sera of the participating patients, the ®ve different CAT tests were performed. A number of patients had participated in a previous study (Land et al., 1998) , but for the present study all serum samples were retested. Finally, data obtained at laparoscopy were correlated to the serological test results.
Serological methods
All assays and calculations were performed according to the manufacturer's instructions. For each test, all sera were tested simultaneously using the same batch of test kits, to avoid inter-test variability.
MIF Biomerieux
Chlamydia trachomatis-spot IF test (Biomerieux). In this indirect uorescent IgG antibody test, C. trachomatis L2 is used as a group antigen. A positive reaction is characterized by speci®c¯uorescence of the C. trachomatis elementary bodies. For quantitative determination serial dilutions are made. In this study all slides were evaluated independently by two readers. In case of disagreement, the judgement of a third reader was decisive. In this study a third reader was needed in four cases.
MIF Labsystems
Chlamydia pneumoniae IgG/IgM micro-IF test (Labsystems, Finland) . In this species-speci®c MIF test C. pneumoniae, C. trachomatis and C. psittaci elementary bodies are used as antigens. In order to diminish cross-reactivity, the immunological activity of chlamydia LPS in C. pneumoniae and C. trachomatis antigens has been reduced. In this study the test was used to detect anti-C. trachomatis and anti-C. pneumoniae IgG antibodies. A positive reaction is characterized by speci®c¯uorescence of the respective elementary bodies. For quantitative determination serial dilutions are made. In this study all slides were evaluated independently by two readers. In case of disagreement, the judgement of a third reader was decisive. In this study a third reader was needed in three cases.
ELISA Labsystems
Chlamydia trachomatis IgG EIA (Labsystems). In this indirect enzyme immunoassay synthetic peptides are used, which are derived from MOMP of C. trachomatis (Na Èrva Ènen et al., 1997) . The optical density of the test plates is read in a spectrophotometer, and the signal to cut-off indices (SCI) are categorized as negative, equivocal, positive or highly positive.
pELISA Medac
Chlamydia trachomatis-IgG-pELISA (Medac, Germany). Medac has a LPS-based, genus-speci®c test (rELISA) and a species-speci®c ELISA (pELISA) on the market. The pELISA has been used in this study, and according to the manufacturer's information it is based on`a synthetic peptide' from MOMP of C. trachomatis. The optical density of the test plates is read in a spectrophotometer, and the SCI are categorized as negative, equivocal, or positive.
ELISA Savyon
Sero-CT-IgG (Savyon, Israel). In this ELISA C. trachomatis speciesspeci®c peptides, derived from`different serotypes' are used. The optical density of the test plates is read in a spectrophotometer, and the SCI are categorized as negative, equivocal, or positive.
Statistical methods
The outcomes of the ®ve tests were compared with the ®ndings at laparoscopy in order to determine their prognostic value of tubal factor subfertility. Sensitivity, speci®city, positive predictive value (PPV), negative predictive value (NPV), likelihood ratio (LR), odds ratio (OR) and 95% con®dence interval (CI) were calculated.
For comparison of LR of the results of the CAT tests, the c 2 -test was used. To test the difference between OR of the different tests, the bootstrap technique was used (Efron and Tibshiram, 1993) . Two-sided P < 0.05 was considered signi®cant. A stepwise logistic regression analysis was used to select the best combination of tests. For evaluation of agreement between tests, k was calculated, and k > 0.7 was considered to indicate good agreement. For comparison of the distributions of C. pneumoniae titres in patients with a positive and negative chlamydia antibody test respectively, the Mann±Whitney Utest was used. P < 0.05 was considered signi®cant.
Results
In 315 subfertile women, results of ®ve different CAT tests and laparoscopy were available for analysis. In 51 patients (16%) tubal pathology was found at laparoscopy. In Table I results are given for each test, re¯ecting its accuracy in predicting tubal factor subfertility. The effect of using different cut-off levels for a positive test is shown. Within each test, increase of the cut-off titre or SCI increased speci®city and PPV at the expense of sensitivity. When using 32 or 64 as the cut-off level for a positive test, the OR of MIF Labsystems differed signi®cantly from all OR of the other four CAT tests. For further analyses, not all different cut-off levels and SCI were used. MIF Biomerieux and MIF Labsystems were considered positive if the IgG titre was b32, ELISA Labsystems was considered positive if SCI was positive or highly positive, and pELISA Medac and ELISA Savyon if SCI was positive.
When MIF Biomerieux was used, 132 women had a positive CAT test, 52 women had a positive test by MIF Labsystems, 53 by ELISA Labsystems, 62 by pELISA Medac and 87 women had a positive test when ELISA Savyon was used (Table I ).
The OR of MIF Labsystems (15.7) was signi®cantly better than the OR of all other tests evaluated. pELISA Medac had the highest OR (8.2) of the three ELISA tests.
In 158 patients all ®ve CAT tests were negative, 67 patients had one positive test, 25 patients had two positive tests, 18 patients had three positive tests, 20 patients had four positive tests and in 27 patients all ®ve tests were positive. Table II gives the number of positive CAT tests in 315 patients. The likelihood of tubal factor subfertility was correlated to the number of positive tests. A statistically signi®cant difference was found between the LR of three, four and ®ve simultaneously positive tests as compared with the LR of one positive test only.
The impact of combining two different tests on the predictive value for tubal factor subfertility was studied. Three different strategies were evaluated. First, a stepwise logistic regression analysis was performed to investigate whether combinations of tests would perform better than the best single CAT test (i.e. MIF Labsystems). From the logistic regression analysis it could be concluded that the diagnostic performance of MIF Labsystems could not be improved signi®cantly by adding another CAT test.
As a second strategy the CAT tests were divided into two groups: the ELISA tests, as they can be automated, and the more laborious MIF tests. Based on stepwise logistic regression analysis with the three ELISA tests in the ®rst block and the two MIF tests in the second block, pELISA Medac was chosen as the ®rst test, and MIF Labsystems as the second test (Table III) . In retesting of initially positive sera, the serial set was considered positive if the second test was also positive, and in retesting of initially negative sera the serial set was considered negative if the second test was also negative. Using pELISA Medac on all serum samples, 62 patients (20%) had a positive test. After retesting these 62 sera by MIF Labsystems, 44 sera (14%) remained positive. An initial negative test was found in 253 patients (80%), and after retesting these 253 sera, 245 were negative (78%). The results of serial testing with the chosen set of CAT tests (i.e. pELISA Table I ).
In the third strategy, it was hypothesized that the two CAT tests which differed most from each other may cover a wider spectrum of serotypes, and act complementarily in identifying women with tubal pathology. In order to select the two tests to be used in the model, the agreement between the ®ve tests was established (Table IV) . For evaluation of the third strategy the set with the lowest k value, i.e. ELISA Labsystems and MIF Biomerieux (k = 0.43), was performed on all serum samples. The result of the set was de®ned as positive if both tests were positive, whereas all other combinations of test results were considered negative. The result of the set was considered negative if both tests had a negative test result, and all other combinations of test results were considered positive. The results of serial testing with the low k set are given in Table III . The OR of the low k set (4.4 and 4.8 respectively) did not differ signi®cantly from the OR of the single tests of which the sets were composed (4.0 for ELISA Labsystems and 4.7 for MIF Biomerieux respectively; Table I ). This indicates that serial testing with the two CAT tests which differed most from each other could not improve the predictive value of CAT.
In order to study cross-reactivity with C. pneumoniae antibodies in the ®ve CAT tests, in all 315 patients C. pneumoniae IgG antibody titres were determined by MIF Labsystems. In 41 patients the IgG titre was <8, in ®ve patients it was 8, in 33 patients it was 16, in 61 patients it was 32, in 83 patients it was 64, in 56 patients it was 128, in 20 patients it was 256 and in 16 patients it was >256. Based on the results of the CAT test, patients were divided into two groups, i.e. those with a positive test result (ELISA positive or highly positive, or MIF titre b32) and those with a negative test result. The distribution of the C. pneumoniae antibody titres in the CAT positive patients was compared with the distribution in the CAT negative patients. This comparison was made for all ®ve CAT tests separately. Signi®cant differences were found between the distributions of C. pneumoniae antibodies in the CAT positive and CAT negative patients when CAT was performed by MIF Biomerieux (P < 0.00001), MIF Labsystems (P = 0.001), ELISA Labsystems (P = 0.02) or ELISA Savyon (P = 0.02), whereas no signi®cant difference was found by pELISA Medac (P = 0.06). This suggests signi®cant cross-reactivity with C. pneumoniae antibodies in all CAT tests evaluated, except in pELISA Medac.
Discussion
Active genital tract infections with C. trachomatis can be diagnosed by direct detection of the micro-organism from the infected site. After the acute episode however, the organism may not be detectable any longer, and chlamydia antibodies in serum may be the only indication of previous chlamydia involvement. The aim of screening subfertile women by CAT is to identify patients with previous C. trachomatis infections, who are at increased risk for tubal pathology. It has become evident, however, that not all women develop C. trachomatis antibodies after chlamydia infection (Schachter et al., 1979) , and that not all women with antibodies have tubal pathology. Although the immunopathology underlying chlamydia infection is still poorly understood, antibody tests have been developed for clinical application. The information provided by the manufacturers about the antigenic epitopes used in their tests is very limited, and is restricted to statements that the test contains`a' or`some' speci®c peptides. Furthermore, manufacturers modify the epitopes used in their tests, which may remain unnoticed by the customers who therefore cannot anticipate changes in test performance. The present study is a clinical comparison of ®ve commercially available chlamydia antibody tests in their ability to predict tubal pathology in subfertile women. Four of these tests had not been evaluated as screening tests for tubal factor subfertility before. We are aware that the results of the study show the diagnostic performances of the tests at a given moment in time only.
In the present study, CAT results were compared with the ®ndings at laparoscopy, and therefore only women who had undergone a laparoscopy were included. Patients with low chlamydia antibody titres are less likely to have tubal pathology and were less likely to be included in the study, since many will have conceived before laparoscopy can be done. This veri®-cation bias (Mol et al., 1999) will in¯uence predictive values of CAT, which are dependent on the prevalence of disease. Veri®cation and selection bias is hard to prevent in clinical studies, however, unless one is prepared to perform the complete fertility investigation of a patient on a single day. Although the bias will result in overestimation of the LR, the overestimation will be similar for all tests investigated.
In comparing the ®ve CAT tests, considerable variation was found in the number of patients with a positive test (Table I ). An IgG titre b32 was found in 132 women using MIF Biomerieux and in 52 using MIF Labsystems, 53 had a positive test by ELISA Labsystems, 62 by pELISA Medac and 87 by ELISA Savyon. The tests with the highest number of positive test results had the lowest PPV, indicating the highest rates of false positive test results. False positive CAT results (i.e. positive CAT tests in patients without tubal pathology at laparoscopy) may be explained by cross-reactivity with C. pneumoniae antibodies, which can be found in~70% of subfertile women (Gijsen et al., 2001) . In this study a signi®cant correlation was found between C. pneumoniae antibody titres and CAT results in four tests, in particular in MIF Biomerieux (P < 0.00001). This con®rms the ®ndings of our previous study using a C. pneumoniae IgG ELISA, in which we found cross-reactivity to occur between C. pneumoniae and C. trachomatis antibodies in MIF Biomerieux. Since the only CAT test (pELISA Medac) in which no signi®cant correlation with the distribution of C. pneumoniae titres was found did not have the highest PPV, cross-reactivity with C. pneumoniae antibodies does not seem to be the only explanation for the high rates of false positive test results obtained in the CAT tests. Since not all women with chlamydia antibodies have tubal pathology at laparoscopy, it has been suggested that genetic factors in the host may also play a role, by modulating immune defence mechanisms and the development of late sequelae (Kinnunen et al., 2002) .
Comparing MIF and ELISA, the results (Table I) suggest that ELISA tests tend to have lower sensitivity and NPV, i.e. more false negative test results. In ELISA tests chosen for this study, speci®c synthetic peptides are used which are considered analogous to the serotype-speci®c antigenic determinants of MOMP of C. trachomatis (Na Èrva Ènen et al., 1997) . These serotype-speci®c determinants differ between tests, and may explain the differences found in test performances between ELISA tests of different manufacturers. Furthermore, tests based on highly speci®c peptides may be so speci®c that they are not able to detect all relevant antigens (Bas et al., 2001) . Variants of serotypes have been identi®ed in urogenital isolates (Morre Â et al., 1998) and mutations have been shown to occur in positions within MOMP (Dean et al., 2000) . Consequently, highly speci®c tests may not be able to identify all serotypes involved in chlamydia infection, and cause false negative CAT results (i.e. negative CAT tests in patients with tubal pathology at laparoscopy).
There are a few reports in the literature on the diagnostic accuracies of different antibody tests for C. trachomatis, in which the tests evaluated in our study have been included. In these studies either tubal pathology, or the direct demonstration of the micro-organism in the genital tract, have been used as reference standards for the serological tests. Each reference standard has its limitations, however. Since tubal pathology can be caused by other micro-organisms in addition to C. trachomatis, it is obvious that tests based on chlamydia antibodies will be imperfect in predicting all tubal pathology. Studies in which the direct detection of the micro-organism is used as a reference have also limited diagnostic accuracy (Chernesky et al., 1998; Bas et al., 2001) , since super®cial infections may provide a poor stimulus for antibody formation. Paukku et al. (1998) did not ®nd a signi®cant difference between the presence of IgG antibodies in 78 patients with tubal factor subfertility, using a modi®ed MIF test and ELISA Labsystems. In a serological follow-up study of 16 women with C. trachomatis positive cervical swabs, ELISA Labsystems, ELISA Savyon and a MIF test have been used . ELISA Labsystems was found to be the most sensitive test, and it was concluded that ELISA Savyon did not cover all chlamydia serotypes. Morre Â et al. (2002) studied the IgG prevalences in 43 women with PCR positive cervical swabs and 106 PCR negative women. Results obtained by two in-house MIF tests were compared with results by ELISA Labsystems, pELISA Medac and ELISA Savyon. The authors concluded that the ELISA tests performed as well as the MIF tests.
In the present study the likelihood of tubal factor subfertility improved as the number of positive CAT tests in a patient increased (Table II) . Compared with one positive CAT test, the LR improved signi®cantly in patients in whom three, four or ®ve positive tests were found. But from a clinical point of view, performing more than two CAT tests in patients is impractical and expensive. Therefore, we evaluated whether two serially performed tests could be of any bene®t in predicting tubal factor subfertility. First, from a stepwise logistic regression analysis it was concluded that the diagnostic performance of the best single CAT test (i.e. MIF Labsystems) could not be improved by adding a second CAT test. Second, we evaluated the performance of a serial set of tests from a laboratory perspective, by constructing a model in which Table III it can be concluded that the low k set of tests (ELISA Labsystems and MIF Biomerieux) did not improve the predictive value of CAT signi®cantly, compared with the predictive values of the single tests of which the set was composed. Therefore the hypothesis of complementary testing with the set of tests with low k had to be rejected.
The results of the present study show that there still is no excellent screening test for tubal pathology in subfertile women. In order to develop more accurate tests for the prediction of chlamydia-associated tubal pathology, future research should focus on the immunopathology of chlamydia infections. Evidence exists that patients with chronic, persisting chlamydia infections are particularly at risk for developing late sequelae. Although IgG antibodies are markers of a previous infection, they do not re¯ect an ongoing chronic in¯ammation properly. Candidates to be introduced into screening for tubal factor subfertility, in addition to speci®c C. trachomatis IgG antibodies, are anti-HSP60 and anti-LPS antibodies. HSP60 has been shown to play a prominent role in chronic in¯ammation and scarring (Claman et al., 1997) , and anti-LPS antibodies might be indicators of ongoing chlamydia infection (Tuuminen et al., 2000) .
In conclusion, although ELISA tests have been claimed to be highly sensitive and speci®c, in the present study they were not superior in predicting tubal factor subfertility. Of the ®ve CAT tests evaluated, MIF Labsystems had the best diagnostic performance, and among the three ELISA tests, pELISA Medac performed best. MIF Biomerieux had the largest number of false positive test results, probably due to crossreactivity with C. pneumoniae antibodies. Combining two different CAT tests did not improve the predictive value for tubal factor subfertility. Health care evaluation from an economic perspective has to prove whether serial testing with the automated pELISA Medac as a ®rst test, and retesting of all positive serum samples with the more laborious MIF Labsystems, is to be preferred to testing of all samples with MIF Labsystems only.
